Abstract:
The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X", Z 1 , Z 2 , n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6, , R 7 , and R 8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.
Abstract:
The present disclosure provides nicotinate/nicotinamide riboside compounds or derivatives of formula (I): wherein X - , Z 1 Z 2 , n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are described herein, reduced analogs thereof, and synthetic processes for the preparation thereof.
Abstract:
A synthetic process is provided for the preparation of phosphorylated analogs of nicotinamide riboside ("NR") having the formula (I), or salts thereof, and reduced or modified derivatives thereof, having the formula (II), wherein X - , Y 1 , Y 2 , Z 1 , Z 2 , n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined herein. The present disclosure also relates to the preparation of phosphorylated analogs of nicotinic acid riboside ("NAR") having the formula (I), or salts thereof, and reduced or modified derivatives thereof, having the formula (II). Generally solvent-free conditions are employed using appropriate mechano-chemical techniques as described. (I) (II)
Abstract:
Derivatives of nicotinic acid riboside (NAR), nicotinamide riboside (NR), and reduced NAR and NR, including 1-(2', 3', 5'-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (4a), and compositions containing the same and/or reduced derivative forms of nicotinamide riboside including 1-(2',3',5'-triacetyl-beta-D-ribofuranosyl)-1,4-nicotinamide (2), are provided for use in the care of treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosmetic compositions containing one or more NR, NAR, NRH, or NARH derivatives, or prodrugs or salts thereof. In further embodiments, the invention relates to methods of using one or more NR, NAR, NRH, or NARH derivatives, or prodrugs, solvates, or salts thereof, to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival and overall cell and tissue health.
Abstract:
The invention relates to methods of preparing nicotinamide riboside and derivatives thereof. In an aspect, the invention relates to a method of preparing a compound of formula (I), wherein n is 0 or 1; m is 0 or 1; Y is O or S; R 1 is selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted primary or secondary amino, and substituted or unsubstituted azido; R 2 - R 5 , which may be the same or different, are each independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, and substituted or unsubstituted aryl; and X - is an anion, selected from an anion of a substituted or unsubstituted carboxylic acid, a halide, a substituted or unsubstituted sulfonate, a substituted or unsubstituted phosphate, a substituted or unsubstituted sulfate, a substituted or unsubstituted carbonate, and a substituted or unsubstituted carbamate.
Abstract translation:本发明涉及制备烟酰胺核苷及其衍生物的方法。 一方面,本发明涉及制备式(I)化合物的方法,其中n为0或1; m为0或1; Y为O或S; R 1选自H,取代或未取代的烷基,取代或未取代的烯基,取代或未取代的炔基,取代或未取代的芳基,取代或未取代的伯或仲氨基,以及取代或未取代的叠氮基; R 2 -R 5可以相同或不同,各自独立地选自H,取代或未取代的烷基,取代或未取代的烯基,取代或未取代的炔基和取代或未取代的芳基; 并且X是阴离子,其选自取代或未取代的羧酸的阴离子,卤化物,取代或未取代的磺酸酯,取代或未取代的磷酸酯,取代或未取代的硫酸酯,取代或未取代的碳酸酯, 未取代的氨基甲酸酯。
Abstract:
The present invention is directed to lactones of the following structural formula for use as precursors of NAD, and their use as nutritional supplements.
Abstract:
A process is provided for microencapsulating nicotinamide riboside (NR), and other NR derivatives by using ethyl cellulose which may be polymerized in a particular manner. Further, compositions comprising NR or derivatives thereof microencapsulated in an edible biopolymer are provided.
Abstract:
Methods for stabilizing or encapsulating at least one compound selected from the group consisting of nicotinamide riboside (NR), nicotinic acid riboside (NAR), nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), derivatives thereof, or salts thereof, are provided. Compositions including wax prills, stabilized, or encapsulated forms of at least one compound selected from the group consisting of nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, are also provided.
Abstract:
The present disclosure provides crystalline Form II of nicotinic acid riboside, crystalline Form II of nicotinic acid riboside triacetate, and methods of preparation thereof. In an embodiment, the present disclosure relates to crystalline forms of nicotinoyl ribosides, derivatives thereof, or salts, hydrates, solvates, or prodrugs thereof. In another embodiment, the present disclosure relates to synthetic sequences or processes that enable the efficient production of crystalline forms of nicotinoyl ribosides, derivatives thereof, or salts, hydrates, solvates, or prodrugs thereof.